Pfizer's Lyrica fails to best placebo in back pain; Novartis plots 22 more layoffs in NY; Lundbeck touts new Brintellix data;

@FiercePharma: Germany bans dozens of drugs made by Dr. Reddy's, Unichem, others because of issues at GVK Bio. Story | Follow @FiercePharma

@CarlyHFierce: New financing helps Anergis take allergy vaccine to Phase III. More | Follow @CarlyHFierce

> Pfizer's ($PFE) pain drug Lyrica, its top-selling product, failed a trial in patients with back pain, offering no more improvement than placebo. Report

> Novartis ($NVS) filed official plans for its third phase of layoffs in Suffern, NY; 22 employees will lose their jobs in early April. Report

> Lundbeck rolled out new data on its antidepressant Brintellix, its next-gen drug intended to replace sales lost to Cipralex generics; the study showed that Brintellix improved patients' memory performance. Report

> Alexion Pharmaceuticals says its rare disease treatment Soliris won orphan drug designation in Japan for treatment of patients with myasthenia gravis. Release

> European officials say fewer branded drugmakers struck patent settlements with generics companies in 2013, with 146 deals in Europe that year, compared with 183 in 2012. Report

> Cardiovascular medtech company HeartFlow has tapped former Johnson & Johnson ($JNJ) CEO William Weldon to serve on its board. Release

> Agios Pharmaceutiucals says it set a 1.98 million share stock offering at a price of $110.75 per share, expecting proceeds to hit $220 million. Release

Medical Device News

@FierceMedDev: Startup gains FDA clearance for breast surgery guidance system. Story | Follow @FierceMedDev

@EmilyWFierce: C.R. Bard battling bid from plaintiffs to consolidate pelvic mesh suits. More | Follow @EmilyWFierce

> St. Jude gains CE mark for first pacemaker with MultiPoint Pacing. Article

> Omron partnership to give AliveCor more retail punch. News

Biotech News

@FierceBiotech: Amicus eyes a 2015 EU filing for its rare disease drug with FDA in sight. Article | Follow @FierceBiotech

@DamianFierce: The @nytimes digs into the medicinal ketamine issue, with cameos from Naurex, Cerecor and $JNJ. More | Follow @DamianFierce

> Naurex posts the positive PhIIb data that helped it reel in $80M. Story

> Merck hits a hiccup with its new Ebola vaccine. News

> Bellicum battles for CAR-T spotlight with a $121M IPO pitch. Article

Vaccines News

> Amgen tests T-Vec's combo potential in trial with Merck's Keytruda. More

> Merck Vaccines president Gerberding leaving post for EVP role. Item

> Ebola vaccine makers Merck, GSK, J&J get legal protections in U.S. thanks to HHS declaration. Report

> Merck wins FDA approval for Gardasil follow-up. Story

> PaxVax meets primary endpoints in PhIII cholera vaccine trial. Article

Pharma Manufacturing News

> AstraZeneca closing U.S. plant, costing 180 jobs. Story

> More Novartis jobs cut in New York as plant suffers drawn-out drawdown. Report

> Romark building $110M plant in Puerto Rico. More

> Indonesia's Indofarma and Kimia combine manufacturing, supply chain strengths. News

> Indian drugmakers lambast proposed PET packaging ban. Article

And Finally... Drug-resistant superbugs could cost the global economy as much as $100 trillion by 2050, according to a review by a Goldman Sachs economist in the U.K. Report

Suggested Articles

Following its headline-grabbing presentation at ESC, AZ is out with more data that support Farxiga use in non-diabetic heart failure patients.

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.